Immuno-epidemiologic correlates of pandemic H1N1 surveillance observations: Higher antibody and lower cell-mediated immune responses with advanced age

Journal of Infectious Diseases

Volumn 203, Issue 2, 2011, Pages 158-167

  Skowronski, Danuta M ^a   Hottes, Travis S ^a   McElhaney, Janet E ^a,b   Janjua, Naveed Z ^a   Sabaiduc, Suzana ^a   Chan, Tracy ^a   Gentleman, Beth ^a,b   Purych, Dale ^c   Gardy, Jennifer ^a   Patrick, David M ^a   Brunham, Robert C ^a   De Serres, Gaston ^d   Petric, Martin ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER COASTAL HEALTH RESEARCH INSTITUTE   (Canada)

^c BC Biomedical Laboratories Ltd   (Canada)

^d UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; GAMMA INTERFERON; INTERLEUKIN 10; VIRUS ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CELLULAR IMMUNITY; CHILD; CONTROLLED STUDY; CROSS REACTION; DISEASE SURVEILLANCE; FEMALE; HEMAGGLUTINATION INHIBITION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFLUENZA A; INFLUENZA A (H1N1); INFLUENZA VIRUS A; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H2N2; INFLUENZA VIRUS A H3N2; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEASONAL INFLUENZA; TH1 CELL; TH2 CELL;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFANT; INFANT, NEWBORN; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H2N2 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA, HUMAN; LYMPHOCYTES; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; PANDEMICS; YOUNG ADULT;

EID: 79851497888     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jiq039     Document Type: Article

References (41)

1. Kilbourne ED. Influenza pandemics of the 20th century. Emerg Infect Dis 2006; 12(1):9-14.
2. Belshe RB. The origins of pandemic influenza - lessons from the 1918 virus. N Engl J Med 2005; 353(21):2209-11.
3. Taubenberger JK, Morens DM. 1918 influenza: The mother of all pandemics. Emerg Infect Dis 2006; 12(1):15-22.
4. Reid AH, Fanning TG, Hultin JV, Taubenberger JK. Origin and evolution of the 1918 "Spanish" influenza virus hemagglutinin gene. Proc Natl Acad Sci U S A 1999; 96(4):1651-6.
5. Garten RJ, Davis CT, Russell CA, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009; 325(5937):197-201.
6. Zimmer SM, Burke DS. Historical perspective - emergence of influenza A (H1N1) viruses. N Engl J Med 2009; 361(3):279-85.
7. Myers KP, Olsen CW, Gray GC. Cases of swine influenza in humans: a review of the literature. Clin Infect Dis 2007; 44(8):1084-8. (Pubitemid 46580277)
8. Zarocostas J. World Health Organization declares A (H1N1) influenza pandemic. BMJ 2009; 338:b2425.
9. Neumann G, Noda T, Kawaoka Y. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 2009; 459(7249):931-9.
10. Skowronski DM, De Serres G, Crowcroft NS, et al. Association between the 2008-09 seasonal influenza vaccine pandemic H1N1 illness during the spring-summer 2009: four observational studies from Canada. PLoS Med 2010; 7(4):e1000258.
11. Baker MG, Wilson N, Huang QS, et al. Pandemic influenza A(H1N1)v in New Zealand: the experience from April to August 2009. Euro Surveill 2009; 14(34):pii 19319.
12. Donaldson LJ, Rutter PD, Ellis BM, et al. Mortality from pandemic A/H1N1 2009 influenza in England: public health surveillance study. BMJ 2009; 339:b5213.
13. Louie JK, Acosta M, Winter K, et al. Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA 2009; 302(17):1896-1902.
14. Vaillant L, La Ruche G, Tarantola A, Barboza P. Epidemic Intelligence Team at InVS. Epidemiology of fatal cases associated with pandemic H1N1 influenza 2009. Euro Surveill 2009; 14(33):pii 19309.
15. British Columbia Office of the Provincial Health Officer. B.C.'s response to the H1N1 pandemic: a summary report June 2010, Available at: http://www.health.gov.bc.ca/pho/pdf/PHO-Report-BC-Response-to-the-H1N1-Pandemic- June2010.pdf. Accessed 1 December 2010.
16. McElhaney JE, Xie D, Hager D, et al. T cell responses are better correlates of vaccine protection in the elderly. J Immunol 2006; 176:6333-9.
17. BC Centre for Disease Control. BC influenza surveillance bulletins: 2009-2010, Available at: http://www.bccdc.ca/dis-cond/DiseaseStatsReports/ influSurveillanceReports.htm. Accessed 1 December 2010.
18. Gijzen K, Liu WM, Visontai I, et al. Standardization validation of assays determining cellular immune responses against influenza. Vaccine 2010; 28:3416-22.
19. Committee for Proprietary Medicinal Products. Note for guidance on harmonisation of requirements for influenza vaccines. London: European Agency for the Evaluation of Medicinal Products, 1997. CPMP/BWP/214/96 (circular no. 96-0666):1-22. Available at: http://www.emea.europa.eu/pdfs/human/bwp/021496en. pdf. Accessed 1 December 2010.
20. Potter CW, Oxford JS. Determinants of immunity to influenza infection in man. Br Med Bull 1979; 35(1):69-75. (Pubitemid 9096975)
21. Spellberg B, Edwards JE. Type 1/type 2 immunity in infectious diseases. Clin Infect Dis 2001; 32(1):76-102. (Pubitemid 32150953)
22. Thomas PG, Keating R, Hulse-Post DJ, Doherty PC. Cell-mediated protection in influenza infection. Emerg Infect Dis 2006; 12(1):48-54. (Pubitemid 43143535)
23. Montomoli E. Correlates of protection against influenza. In Rappuoli R, Del Guidice G eds: Influenza vaccines for the future. Basel, Switzerland: Birkhäuser Verlag, 2008: 139-59.
24. de Jong JC, Palache AM, Beyer WEP, Rimmelzwaan GF, Boon ACM, Osterhaus ADME. Haemagglutination-inhibiting antibody to influenza virus. In Brown F, Haaheim LR, Schild GC eds: Laboratory correlates of immunity to influenza - a reassessment. Devl Biol. Vol 115. Basel, Switzerland: Karger, 2003: 63-73.
25. World Health Organization. Seroepidemiological studies of pandemic influenza A (H1N1) 2009 virus. kly Epidemiol Rec 2010; 85:229-36.
26. Hancock K, Veguilla V, Xiuhu L, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009; 361(20):1945-52.
27. Itoh Y, Shinya K, Kiso M, et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 2009; 460(7258);1021-7.
28. Miller E, Hoschler K, Hardelid P, Stanford E, Andrews N, Zambon M. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological survey. Lancet 2010; 375(9720):1100-8.
29. Rizzo C, Rota MC, Bella A, et al. Cross-reactive antibody responses to the 2009 A/H1N1v influenza virus in the Italian population in the prepandemic period. Vaccine 2010; 28(20):3558-62.
30. Morens DM, Burke DS, Halstead SB. The wages of original antigenic sin. Emerg Infect Dis 2010; 16(6):1023-4.
31. Igarashi M, Ito K, Yoshida R, Tomabechi D, Kida H, Takada A. Predicting the antigenic structure of the pandemic (H1N1) 2009 influenza virus hemagglutinin. PLoS One 2010; 5(1):e8553.
32. Reichert T, Chowell G, Nishiura H, Christensen RA, McCullers JA. Does glycosylation as a modifier of original antigenic sin explain the case age distribution and unusual toxicity in pandemic novel H1N1 influenza? BMC Infect Dis 2010; 10:5.
33. Stambas J, Guillonneau C, Kedzierska K, Mintern JD, Doherty PC, La Gruta NL. Killer T cells in influenza. Pharmacol Ther 2008; 120(2):186-96.
34. Tu W, Mao H, Zheng J, et al. Cytotoxic T lymphocytes established by seasonal human influenza cross-react against 2009 pandemic H1N1 influenza virus. J Virol 2010; 84:6527-35.
35. McElhaney JE, Effros RB. Immunosenescence: what does it mean to health outcomes in older adults? Curr Opin Immunol 2009; 21:418-24.
36. Bodewes R, Kreijtz JHCM, Baas C, et al. Vaccination against human influenza A/H3N2 virus prevents the induction of heterosubtypic immunity against lethal infection with avian influenza A/H5N1 virus. PLoS One 2009; 4(5):e5538.
37. Bodewes R, Kreijtz JHCM, Rimmelzwaan GF. Yearly influenza vaccinations: a double-edged sword? Lancet Infect Dis 2009; 9(12):784-8.
38. Laurie KL, Carolan LA, Middleton D, Lowther S, Kelso A, Barr IG. Multiple infections with seasonal influenza A virus induce cross-protective immunity against A(H1N1) pandemic influenza virus in a ferret model. J Infect Dis 2010; 202:1011-20.
39. Mathews JD, Chesson JM, McCaw JM, McVernon J. Understanding influenza transmission, immunity and pandemic threats. Influenza Other Respi Viruses 2009; 3(4):143-9.
40. Graham MB, Braciale VL, Braciale TJ. Influenza virus-specific CD4+ T helper type 2 T lymphocytes do not promote recovery from experimental virus infection. J Exp Med 1994; 180:1273-82. (Pubitemid 24289601)
41. Kaji M, Kobayashi M, Pollard RB, Suzuki F. Influence of type 2 T cell responses on the severity of encephalitis associated with influenza virus infection. J Leukoc Biol 2000; 68:180-6.